Itraconazole associated quadriparesis and edema: a case report
- PMID: 21477327
- PMCID: PMC3080323
- DOI: 10.1186/1752-1947-5-140
Itraconazole associated quadriparesis and edema: a case report
Abstract
Introduction: Itraconazole is an anti-fungal agent widely used to treat various forms of mycosis. It is particularly useful in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. Side effects are uncommon and usually mild. Mild neuropathy is noted to occur very rarely. We present an unusual and, to the best of our knowledge, as yet unreported case of severe neuropathy and peripheral edema due to itraconazole in the absence of a concomitant risk factor.
Case presentation: A 72-year-old Caucasian man was started on itraconazole following diagnosis of severe asthma with fungal sensitization. One month later he presented with severe bilateral ankle edema with an elevated serum itraconazole level. The itraconazole dose was reduced but his ankle edema persisted and he developed weakness of all four limbs. Itraconazole was completely stopped leading to improvement in his leg edema but he became bed bound due to weakness. He gradually improved with supportive care and neurorehabilitation. On review at six months, our patient was able to mobilize with the aid of two elbow crutches and power had returned to 5/5 in distal extremities and 4+/5 in proximal extremities. The diagnosis was established based on the classical presentation of drug-induced neuropathy and negative investigatory findings for any alternative diagnoses.
Conclusion: We report the case of a patient presenting with an unusual complication of severe neuropathy and peripheral edema due to itraconazole. Clinicians should be alert to this association when encountered with neuropathy and/or edema in an itraconazole therapy recipient.
Figures
Similar articles
-
Daily dose of itraconazole 100 mg to treat allergic bronchopulmonary aspergillosis (ABPA) related eosinophilia: a case report.Hippokratia. 2017 Jul-Sep;21(3):144-146. Hippokratia. 2017. PMID: 30479477 Free PMC article.
-
A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab.BMC Pulm Med. 2018 Mar 27;18(1):53. doi: 10.1186/s12890-018-0617-5. BMC Pulm Med. 2018. PMID: 29587693 Free PMC article.
-
Itraconazole-related increased vincristine neurotoxicity: case report and review of literature.J Pediatr Hematol Oncol. 2005 Jul;27(7):389-92. doi: 10.1097/01.mph.0000172751.06286.5b. J Pediatr Hematol Oncol. 2005. PMID: 16012330 Review.
-
Severe asthma with fungal sensitization in a child: response to itraconazole therapy.Pediatrics. 2010 May;125(5):e1255-8. doi: 10.1542/peds.2009-2443. Epub 2010 Apr 12. Pediatrics. 2010. PMID: 20385639
-
[Severe sensory-motor axonal neuropathy following diabetic ketoacidosis].Rinsho Shinkeigaku. 2020 Sep 29;60(9):614-619. doi: 10.5692/clinicalneurol.cn-001433. Epub 2020 Aug 8. Rinsho Shinkeigaku. 2020. PMID: 32779597 Review. Japanese.
Cited by
-
Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents.Drugs. 2019 Jun;79(8):833-853. doi: 10.1007/s40265-019-01127-8. Drugs. 2019. PMID: 31093949 Review.
-
Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going?J Fungi (Basel). 2016 Jun 7;2(2):18. doi: 10.3390/jof2020018. J Fungi (Basel). 2016. PMID: 29376935 Free PMC article. Review.
References
-
- Polak A. Antifungal therapy - state of the art at the beginning of the 21st century. Prog Drug Res. 2003. Spec. No. 59-190. - PubMed
-
- Denning DW, O'Driscoll BR, Powell G, Chew F, Atherton GT, Vyas A, Miles J, Morris J, Niven RM. Randomized Controlled Trial of Oral Antifungal Treatment for Severe Asthma with Fungal Sensitization: The Fungal Asthma Sensitization Trial (FAST) Study. Am J Respir Crit Care Med. 2009;179(1):11–18. doi: 10.1164/rccm.200805-737OC. - DOI - PubMed
-
- Sporanox data sheet. http://medsafe.govt.nz/profs/Datasheet/s/Sporanoxcap.htm
LinkOut - more resources
Full Text Sources